Towards a precision approach to anesthetic/analgesic immunomodulation in cancer DOI Creative Commons
Hersh Gupta, Kay See Tan,

Gregory W. Fischer

и другие.

Frontiers in Anesthesiology, Год журнала: 2024, Номер 3

Опубликована: Дек. 5, 2024

Background Immunomodulation is widely invoked to explain possible effects of anesthetic/analgesic drugs on recurrence and survival in cancer patients. By analogy with immune checkpoint inhibitors, which enhance anti-tumor actions cells the tumor microenvironment (TME), we aim develop a precision approach immunomodulation by drugs. We explore biomarkers predictive immunotherapy response [tumor mutational burden (TMB)] resistance [fraction genome altered (FGA)] relation dose expression drug target receptor genes. Methods Two local clinical cohorts [lung adenocarcinoma (LUAD) colon (COAD) patients] were analyzed retrospectively yield statistical interactions between drugs, outcomes, TMB/FGA (extending previously reported results). Bulk gene data for solid tumors from 6,488 patients across 18 types was obtained The Cancer Genome Atlas (TCGA) normalized type. TMB FGA each TCGA patient sample extracted cBioPortal. DeSeq employed quantify differential receptors 79 common high/low FGA. Localization these specific estimated using CIBERSORT. Results Increased magnified opioid pro-tumor overall LUAD, while increased reduced ketamine did not affect ketorolac recurrence. In COAD, (DNA mismatch repair deficiency) Drug (and cell-type specificity) correlated both as function Conclusions may have utility individual due immunomodulation. Correlation TME cell suggests molecular/omics level targets further mechanistic exploration. A oncoanalgesia ultimately be warranted optimize oncological outcomes.

Язык: Английский

TEMPORARY REMOVAL: Targeting the kappa opioid receptor for analgesia and antitumour effects DOI
David G. Lambert, Joshua S. Mincer

British Journal of Anaesthesia, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Towards a precision approach to anesthetic/analgesic immunomodulation in cancer DOI Creative Commons
Hersh Gupta, Kay See Tan,

Gregory W. Fischer

и другие.

Frontiers in Anesthesiology, Год журнала: 2024, Номер 3

Опубликована: Дек. 5, 2024

Background Immunomodulation is widely invoked to explain possible effects of anesthetic/analgesic drugs on recurrence and survival in cancer patients. By analogy with immune checkpoint inhibitors, which enhance anti-tumor actions cells the tumor microenvironment (TME), we aim develop a precision approach immunomodulation by drugs. We explore biomarkers predictive immunotherapy response [tumor mutational burden (TMB)] resistance [fraction genome altered (FGA)] relation dose expression drug target receptor genes. Methods Two local clinical cohorts [lung adenocarcinoma (LUAD) colon (COAD) patients] were analyzed retrospectively yield statistical interactions between drugs, outcomes, TMB/FGA (extending previously reported results). Bulk gene data for solid tumors from 6,488 patients across 18 types was obtained The Cancer Genome Atlas (TCGA) normalized type. TMB FGA each TCGA patient sample extracted cBioPortal. DeSeq employed quantify differential receptors 79 common high/low FGA. Localization these specific estimated using CIBERSORT. Results Increased magnified opioid pro-tumor overall LUAD, while increased reduced ketamine did not affect ketorolac recurrence. In COAD, (DNA mismatch repair deficiency) Drug (and cell-type specificity) correlated both as function Conclusions may have utility individual due immunomodulation. Correlation TME cell suggests molecular/omics level targets further mechanistic exploration. A oncoanalgesia ultimately be warranted optimize oncological outcomes.

Язык: Английский

Процитировано

1